Skip to content

Study · Animal study (in vivo) · mouse · 1983

5 results

Protective activity of thymosin alpha 1 against tumor progression in immunosuppressed mice.

Ishitsuka H, Umeda Y, Sakamoto A, Yagi Y

Advances in experimental medicine and biology1 Jan 1983Cited by 2 (Europe PMC)

PMID6650286 (opens in a new tab)DOI10.1007/978-1-4757-1410-4_9 (opens in a new tab)PepBankPUB-06650286
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In immunosuppressed mice, thymosin alpha‑1 given with cytostatics or after X-ray prevented the high incidence of pulmonary metastasis of B16 melanoma cells.

    In plain wordsIn immunosuppressed mice, thymosin alpha‑1 prevented the lung spread of melanoma cells.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePulmonary metastasis of B16 melanoma
    Study

    mousen: not reported in source

    Mice immunosuppressed by cytostatics or X-ray irradiation
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Inoculation of B16 melanoma or L1210 leukemic cells into these immunosuppressed mice caused a high incidence of pulmonary metastasis or rapid death, respectively. Thymosin alpha 1 given concomitantly with cytostatics or after X-ray prevented such deleterious effects of these agents.
    1 context sentence
    Summary · context
    The effect of thymosin alpha 1 was examined in mice immunosuppressed by cytostatics or X-ray irradiation.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In immunosuppressed mice, thymosin alpha‑1 given with cytostatics or after X-ray prevented the rapid death caused by L1210 leukemic cells.

    In plain wordsIn immunosuppressed mice, thymosin alpha‑1 prevented the rapid death caused by leukemia cells.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseRapid death after L1210 leukemia inoculation
    Study

    mousen: not reported in source

    Mice immunosuppressed by cytostatics or X-ray irradiation
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Inoculation of B16 melanoma or L1210 leukemic cells into these immunosuppressed mice caused a high incidence of pulmonary metastasis or rapid death, respectively. Thymosin alpha 1 given concomitantly with cytostatics or after X-ray prevented such deleterious effects of these agents.
    1 context sentence
    Summary · context
    The effect of thymosin alpha 1 was examined in mice immunosuppressed by cytostatics or X-ray irradiation.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    Thymosin alpha‑1 prevented the reduction of NK cell activity caused by cytostatics or X-ray in mice.

    In plain wordsIn immunosuppressed mice, thymosin alpha‑1 prevented the drop in natural killer cell activity.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNK cell activity after cytostatics or X-ray
    Study

    mousen: not reported in source

    Mice immunosuppressed by cytostatics or X-ray irradiation
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosin alpha 1 prevented the reduction of NK cell activity caused by these agents.
    1 context sentence
    Summary · context
    The effect of thymosin alpha 1 was examined in mice immunosuppressed by cytostatics or X-ray irradiation.
  4. 04AnimalAnimal study (in vivo)Mechanism

    The preventive activity transferred to immunosuppressed recipients by spleen cells and by T-cell-deprived cells, but not by NK-cell-deprived cells.

    In plain wordsIn mice, protection by thymosin alpha‑1 passed to immunosuppressed recipients through spleen cells, but not through spleen cells without NK cells.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableTransfer of preventive activity by spleen cells
    Study

    mousen: not reported in source

    Mice immunosuppressed by cytostatics or X-ray irradiation
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The preventive activity could be transferred to immunosuppressed recipients by spleen cells and those deprived of T cells, but not by those deprived of NK cells.
    1 context sentence
    Summary · context
    The effect of thymosin alpha 1 was examined in mice immunosuppressed by cytostatics or X-ray irradiation.
  5. 05AnimalAnimal study (in vivo)Mechanism

    When thymosin alpha‑1 was given with 5-FU, the tissue distribution of 125I-L1210 cells was almost the same as in normal mice, unlike the altered pattern with 5-FU alone.

    In plain wordsIn mice given 5-FU, thymosin alpha‑1 kept the spread of leukemia cells in the body close to that in normal mice.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedTissue distribution of 125I-L1210 cells in 5-FU-treated mice
    Study

    mousen: not reported in source

    Mice immunosuppressed by cytostatics or X-ray irradiation
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In 5-FU-treated mice, distribution of 125I-L1210 cells upon inoculation was higher in blood and lung, but lower in liver and spleen as compared with that in normal mice. On the other hand, when thymosin alpha 1 was given with 5-FU, the pattern of the tissue distribution was almost the same as that in normal mice.
    1 context sentence
    Summary · context
    The effect of thymosin alpha 1 was examined in mice immunosuppressed by cytostatics or X-ray irradiation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.